325 related articles for article (PubMed ID: 17454265)
21. beta-Glycosphingolipids as immune modulators.
Adar T; Ilan Y
J Immunotoxicol; 2008 Apr; 5(2):209-20. PubMed ID: 18569392
[TBL] [Abstract][Full Text] [Related]
22. The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice.
Cardell SL
Clin Exp Immunol; 2006 Feb; 143(2):194-202. PubMed ID: 16412042
[TBL] [Abstract][Full Text] [Related]
23. [iNKT cells, a friend or a foe for autoimmune disease and allergy?].
Miyake S
Nihon Rinsho Meneki Gakkai Kaishi; 2006 Feb; 29(1):27-36. PubMed ID: 16505600
[TBL] [Abstract][Full Text] [Related]
24. Invariant NKT cells and tolerance.
Nowak M; Stein-Streilein J
Int Rev Immunol; 2007; 26(1-2):95-119. PubMed ID: 17454266
[TBL] [Abstract][Full Text] [Related]
25. Invariant NKT and NKT-like lymphocytes: two different T cell subsets that are differentially affected by ageing.
Peralbo E; Alonso C; Solana R
Exp Gerontol; 2007 Aug; 42(8):703-8. PubMed ID: 17604928
[TBL] [Abstract][Full Text] [Related]
26. Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells.
Metelitsa LS
Clin Immunol; 2004 Mar; 110(3):267-76. PubMed ID: 15047204
[TBL] [Abstract][Full Text] [Related]
27. Diverse CD1d-restricted T cells: diverse phenotypes, and diverse functions.
Behar SM; Cardell S
Semin Immunol; 2000 Dec; 12(6):551-60. PubMed ID: 11145861
[TBL] [Abstract][Full Text] [Related]
28. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
Paget C; Mallevaey T; Speak AO; Torres D; Fontaine J; Sheehan KC; Capron M; Ryffel B; Faveeuw C; Leite de Moraes M; Platt F; Trottein F
Immunity; 2007 Oct; 27(4):597-609. PubMed ID: 17950005
[TBL] [Abstract][Full Text] [Related]
29. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
Front Immunol; 2018; 9():1266. PubMed ID: 29928278
[TBL] [Abstract][Full Text] [Related]
30. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
Gigli G; Caielli S; Cutuli D; Falcone M
Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
[TBL] [Abstract][Full Text] [Related]
31. Involvement of the CD1d-natural killer T cell pathway in neointima formation after vascular injury.
Ström A; Wigren M; Hultgårdh-Nilsson A; Saxena A; Gomez MF; Cardell S; Fredrikson GN; Nilsson J
Circ Res; 2007 Oct; 101(8):e83-9. PubMed ID: 17885216
[TBL] [Abstract][Full Text] [Related]
32. Activation of natural killer T cells by glycolipids.
Tupin E; Kronenberg M
Methods Enzymol; 2006; 417():185-201. PubMed ID: 17132506
[TBL] [Abstract][Full Text] [Related]
33. Immunology. The elusive NKT cell antigen--is the search over?
Godfrey DI; Pellicci DG; Smyth MJ
Science; 2004 Dec; 306(5702):1687-9. PubMed ID: 15576595
[No Abstract] [Full Text] [Related]
34. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
Van Kaer L
Nat Rev Immunol; 2005 Jan; 5(1):31-42. PubMed ID: 15630427
[TBL] [Abstract][Full Text] [Related]
35. CD1d-mediated antigen presentation to natural killer T (NKT) cells.
Brutkiewicz RR; Lin Y; Cho S; Hwang YK; Sriram V; Roberts TJ
Crit Rev Immunol; 2003; 23(5-6):403-19. PubMed ID: 15030309
[TBL] [Abstract][Full Text] [Related]
36. Innate self recognition by an invariant, rearranged T-cell receptor and its immune consequences.
Stanic AK; Park JJ; Joyce S
Immunology; 2003 Jun; 109(2):171-84. PubMed ID: 12757612
[TBL] [Abstract][Full Text] [Related]
37. Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis.
Kaieda S; Tomi C; Oki S; Yamamura T; Miyake S
Arthritis Rheum; 2007 Jun; 56(6):1836-45. PubMed ID: 17530712
[TBL] [Abstract][Full Text] [Related]
38. Exploiting CD1-restricted T cells for clinical benefit.
Exley MA; Dellabona P; Casorati G
Mol Immunol; 2021 Apr; 132():126-131. PubMed ID: 33582549
[TBL] [Abstract][Full Text] [Related]
39. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.
Mattner J; Debord KL; Ismail N; Goff RD; Cantu C; Zhou D; Saint-Mezard P; Wang V; Gao Y; Yin N; Hoebe K; Schneewind O; Walker D; Beutler B; Teyton L; Savage PB; Bendelac A
Nature; 2005 Mar; 434(7032):525-9. PubMed ID: 15791258
[TBL] [Abstract][Full Text] [Related]
40. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
Kronenberg M
J Vis Exp; 2007; (10):635. PubMed ID: 18989407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
